Skip to main content
Fig. 4 | BMC Gastroenterology

Fig. 4

From: Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis

Fig. 4

Network meta-analysis comparisons for side effect. Data are SMD (95% CI) in the column-defining treatment compared with the row-defining treatment. Taking SMD = 0 as the standard, negative value represents the strong decreasing effect or weak increasing effect on the index, while positive value represents the weak decreasing effect or strong increasing effect on the index. (a) changes in eGFR, (b) changes in creatinine, (c) changes in bone mineral density, and (d) changes in blood phosphorus

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us